ITEN to Launch the Industrial-Scale Production of Its All-Solid-State Battery Powency Product Family
8.11.2024 09:00:00 CET | Business Wire | Press release
Electronica 2024 Trade Fair--ITEN, a pioneer in the development and production of solid-state batteries for electronics markets, today announced the production launch of its new Powency family of rechargeable Li-ion batteries. The new family consists of high-power density batteries, including for now the PWY0150S battery, available in pre-production, and the PWY0250S battery, available as engineering samples. Those first Powency batteries respectively have a capacity of 150µAh and 250µAh. The Powency product family, which is manufactured at the ITEN facility in France, is a testament to the demonstration of ITEN's technological and industrial leadership in the field of solid-state batteries.
ITEN will participate in the Electronica trade show in Munich from November 12 to 15, 2024 (Hall B4 - Stand E05) to showcase both PWY0150S and PWY0250S.
Powency PWY0150S and PWY0250S, solid-state energy storage in an unmatched form factor
The Powency PWS0150S and PWS0250S batteries are designed to deliver energy peaks to connected devices or to power electronic systems during a power outage. Both products feature a high-power density in an ultra-compact design, measuring 25mm³ and weighing 73 milligrams; they can supply the current levels required by connected devices operating with LAN wireless protocols. The Powency PWS0150S and PWS0250S are available as SMD devices, enabling an easy integration with automated production lines. Powency PWS0150S and PWS0250S are based on ITENS' all-solid-state battery technologies, contain no heavy metals, toxic chemicals or organic solvents, and can be recycled as passive electronic components.
Powency PWY0150S and PWY0250S, designed to address the energy efficiency challenges for the IoT and maintenance-free wireless sensors
Powering low-power, small-form-factor devices is a major obstacle in the emergence and broad implementation of the Internet of Things (IoT). The Powency products will enable IoT device makers to build high-performance Bluetooth Low Energy (BLE), 802.15.4, or NFC systems in an unrivaled form factor. They facilitate the widespread use of maintenance-free devices that harvest energy from external sources such as indoor or outdoor ambient light, ambient radio waves, and / or kinetic motion. PWY0150S is currently being manufactured in pre-series for numerous early-stage customers and serves as the ideal energy reservoir in autonomous sensors that are powered by Energy Harvesting.
Powency PWY0150S and PWY0250S, "Sustainability by design, process, and function"
The Powency product family, like all ITEN-developed products, is designed and manufactured to minimize its environmental impact and adhere to the company’s motto "sustainability by design, by process and by function." ITEN batteries are composed of ceramic, and are free of organic materials and critical metals like cobalt. They are rechargeable and completely recyclable.
Vincent Cobée, CEO of ITEN, said: "Our presence at the Electronica Trade Show, this essential event in the electronics industry, is very important for ITEN, at a key moment in the company’s growth. The commercial introduction and mass production of the Powency product family have indeed marked a significant milestone in the company's evolution. We were able to develop solutions that the market expected, in terms of both product and integration into our clients' various industrial processes, to provide a sustainable, high-performance, and genuinely integrated response. The trajectory will be further accelerated in the upcoming months by the introduction of a new battery that is even more potent, as well as the offering of two distinct solutions.”
More information available on www.iten.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20241101283870/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CorFlow Therapeutics Announces Successful Completion of Phase 1 and First Patients Enrolled in Phase 2 of the MOCA II Pivotal Trial, Approval to Start the REVITALISE RCT in Europe, and Strengthening of Clinical Leadership30.4.2026 13:00:00 CEST | Press release
Milestones advance clinical progress and path to commercialization CorFlow Therapeutics AG (CorFlow), a clinical-stage company focused on transforming the diagnosis and treatment for heart attack patients, today announced multiple milestones in advancing its clinical program and the strengthening of clinical leadership. Phase 1 of the company’s MOCA II FDA Pivotal Trial was successfully reached after safety and performance goals were met with STEMI heart attack patients who had the proprietary PCoFI diagnostic measurement of microvascular obstruction (MVO) made during a stenting procedure, when compared to the reference standard diagnosis by cardiac MRI in the subsequent days. Phase 1 included 19 patients enrolled across 5 US and 3 European sites. MOCA II follows the FIH MOCA I study and primarily aims to validate the threshold value of the proprietary PCoFI measurement for diagnosing MVO in the setting of primary angioplasty compared to cardiac MRI. This milestone achievement, which w
Agendia to Present New Data Demonstrating the Expanded Clinical Utility of MammaPrint® and BluePrint® at the 2026 ESMO Breast Cancer Annual Congress30.4.2026 13:00:00 CEST | Press release
Poster presentations highlight the prognostic value of MammaPrint + Blueprint in small, node-negative tumors and impact of BMI on recurrence dynamics Agendia®, Inc., a leader in precision oncology for breast cancer, today announced it will present new data at the 2026 European Society for Medical Oncology (ESMO) Annual Congress on Breast Cancer, taking place May 6-8 in Berlin, Germany. The company will present two posters featuring data from the prospective FLEX Study and an independent post hoc analysis of the landmark MINDACT trial that underscore the prognostic value of MammaPrint® + BluePrint® in early-stage breast cancer (EBC). Poster #65P | Thursday, May 7, 13:15 – 14:15 p.m. CEST | Presenter: Elena Shagisultanova Prognostic Performance of MammaPrint in Patients with Small T1a, b, and c Node-Negative Early Breast Cancer A retrospective analysis from the FLEX Study involving 4,349 patients highlights the biological heterogeneity within small, node-negative (T1a, b, and c) tumors –
The Biggest Predictor of Business Growth Is Behavior30.4.2026 09:00:00 CEST | Press release
New IDEO research reveals a gap in the behaviors that most drive growth: long-term vision, rapid experimentation, and team autonomy—with only 10% of leaders saying their company excels at the combination. IDEO, the global design and innovation company, today announced the IDEO Innovation Quotient (IDEO IQ), a new report measuring how workplace behaviors drive business performance across 100 of the world’s largest companies. Those with the highest IDEO IQ scores earned nearly $20 billion in profit last year—50% higher than average and three times more than those ranked at the bottom. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429978890/en/ The IDEO Innovation Quotient (IDEO IQ) is a new report measuring how workplace behaviors drive business performance across 100 of the world’s largest companies. The IDEO IQ surveyed 266 leaders in product and innovation roles at 100 of the world’s largest companies across the Media &
Suzano Sells 12.7 Million Tonnes of Pulp for the First Time in Its History30.4.2026 00:22:00 CEST | Press release
Suzano(B3: SUZB3 | NYSE: SUZ), the world’s largest pulp producer, announces its results for the first quarter of 2026 (1Q26), achieving a new all‑time record in pulp sales. Over the 12‑month period from April 2025 to March 2026, the company sold 12.7 million tonnes of pulp, the highest volume ever recorded in its history. During the same period, Suzano also sold 1.7 million tonnes of paper across the packaging, printing and writing, specialty, and tissue segments. This unprecedented sales level mainly reflects the increase in production capacity following the start‑up of the Ribas do Rio Pardo pulp mill in the state of Mato Grosso do Sul, as well as Suzano’s strong operational efficiency across its production lines and supply chains, serving customers in more than 100 countries worldwide. In the first quarter of 2026, Suzano sold a total of 3.2 million tonnes, comprising 2.8 million tonnes of pulp and 378 thousand tonnes of paper. Net revenue amounted to BRL 11.0 billion, while adjuste
The Estée Lauder Companies Announces Minority Investment in Luxury Clinical Skin Care Brand 111SKIN29.4.2026 22:30:00 CEST | Press release
Surgeon-Founded Brand Anchored by Innovative NAC Y2™ Technology The Estée Lauder Companies Inc. (NYSE:EL) today announced a minority investment in 111SKIN, a luxury clinical skin care brand founded by renowned plastic and reconstructive surgeon Dr. Yannis Alexandrides. Terms of the investment were not disclosed. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429495879/en/ 111SKIN's Reparative Collection Founded in 2012, 111SKIN was originally developed by Dr. Alexandrides to accelerate his patients’ healing time following procedures. At the heart of the brand is its innovative NAC Y2™, a pioneering complex designed to support skin repair and maintain a healthy, radiant and resilient complexion. Building on the foundation of this clinical expertise, 111SKIN has developed a portfolio of more than 30 products, anchored by its Black Diamond and Reparative collections and priced from $50 to $1,000. “Skin care is entering a new
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom